Skip to main content
Psych Congress  

Assessment of Adherence and Persistence Among Patients With Major Depressive Disorder Enrolled in the tAccess Patient Support Program

Authors  

Debra Lawrence, MS, MBA,PhD – Takeda Pharmaceuticals U.S.A., Inc.; Janna Manjelievskaia, PhD, MPH – IBM Watson Health; Maëlys Touya, MSc, PharmD – Lundbeck LLC; Lambros Chrones, MD – Takeda Pharmaceuticals U.S.A., Inc.; Maggie McCue, MS, RD – Takeda Pharmaceuticals U.S.A., Inc.

Sponsor  
Takeda Pharmaceuticals U.S.A., Inc.; Lundbeck LLC

Objective: To assess the impact of tAccess patient support program (PSP) on adherence and persistence among adult patients with major depressive disorder (MDD). tAccess PSP, a free program initiated February 20, 2017, by Takeda/Lundbeck, aims to help patients track their treatment as directed by their healthcare provider.

Methods: A retrospective observational cohort study was conducted in MDD patients receiving Trintellix and enrolled in the tAccess PSP. Eligibility criteria were age 18–64 years; ≥1 Trintellix claim; and ≥1 inpatient/outpatient medical MDD claim during the 12 months preceding the index date. Study outcomes included medication persistence and adherence (proportion of days covered [PDC] adherent ≥80%) at 90 days. Persistence was also assessed for patients fulfilling the Healthcare Effectiveness Data and Information Set (HEDIS) Antidepressant Medication Management (AMM) criteria (84- and 180-day follow-up).

Results: The study identified 2,635 patients with MDD diagnosis and ≥90 days of follow-up time and 2,238 patients meeting HEDIS AMM criteria. During 90-day follow-up, 62.1% of patients with MDD were persistent on Trintellix. Mean PDC among all patients with MDD was 0.78. Among patients who met HEDIS AMM criteria, persistence in the tAccess PSP was 83.4% and 69.9% at 84 and 180 days, respectively. For context, in an outside analysis of 2017 HEDIS AMM commercial HMO plan patients, persistence was 67.8% and 51.8% at 84 and 180 days, respectively.

Conclusions: These initial results suggest the tAccess PSP may be beneficial in addressing the clinically relevant issues of treatment adherence and persistence in MDD patients.

This poster was presented at the 32nd annual Psych Congress, held Oct. 3-6, 2019, in San Diego, California.

Back to Top